HighTower Advisors
BHVN

HighTower Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

HighTower Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,361
Closed -$1.57M – 3651
2022
Q3 		$1.57M Sell
10,361
-269
-3% -$39.9K ﹤0.01% 1378
2022
Q2 		$1.55M Sell
10,630
-724
-6% -$92.5K ﹤0.01% 1398
2022
Q1 		$1.35M Sell
11,354
-2,174
-16% -$271K ﹤0.01% 1588
2021
Q4 		$1.86M Buy
13,528
+10,537
+352% +$1.34M ﹤0.01% 1394
2021
Q3 		$416K Buy
+2,991
New +$373K ﹤0.01% 2191
2020
Q3 		– Sell
-6,825
Closed -$500K – 2768
2020
Q2 		$500K Buy
+6,825
New +$363K ﹤0.01% 1459

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

HighTower Advisors's BHVN Position: Q4 2022 in Review

HighTower Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 10,361 shares — an estimated $1.57M sold.

HighTower Advisors first reported a position in BHVN in Q2 2020 and held it in 6 quarters. The position peaked at $1.86M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • HighTower Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • HighTower Advisors sold 10,361 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.57M.
  • HighTower Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 6 quarters.
  • HighTower Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.86M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.